Skip to main
AUTL
AUTL logo

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 82%
Buy 9%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics PLC is focused on developing advanced T-cell therapies for cancer, with a promising pipeline that includes several clinical-stage programs such as Obe-cel, AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8. Despite challenges related to cost of goods sold and potential payer reimbursement issues, positive indicators such as the favorable treatment expected for Obe-cel suggest strong demand from payors. Moreover, mechanistic advantages may enhance Obe-cel's efficacy over existing therapies, adding to the company’s potential for long-term success in the competitive CAR-T market.

Bears say

Autolus Therapeutics has experienced a significant reduction in its sales estimate for obe-cel, with projections decreasing from $83 million to $27 million due to delays in revenue recognition and a pushback of expected EU sales to 2026. This adjustment reflects broader market concerns about the ability of the company's CAR-T therapeutics to meet initial production forecasts, potentially compromising future revenue streams. Additionally, adverse events such as Cytokine release syndrome, neurotoxicity, and severe cytopenias associated with Autolus' therapies may further impede their application and market acceptance, contributing to a negative outlook on the stock.

Autolus Therapeutics (AUTL) has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 82% of analysts recommend a Strong Buy, 9% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Strong Buy based on their latest research and market trends.

According to 11 analysts, Autolus Therapeutics (AUTL) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.